The Atrial FibriLlatiOn Registry (FLOW-AF): Patient Characteristics, Treatment Patterns, and Outcomes in Egypt

Abstract Introduction Real-world data on atrial fibrillation (AF) in the Middle East and North Africa (MENA) region, including Egypt, are sparse. The aim of the FLOW-AF registry was to evaluate the characteristics, treatment patterns, and clinical and economic outcomes of newly diagnosed non-valvula...

Full description

Saved in:
Bibliographic Details
Main Authors: Mohamed Sobhy, Magdy Abdelhamid, Adel Mohamed El Etriby, Mohamed Fathy Soliman Gamaleldin, Ahmed Mohamed Helmy Youssef, Natasha Khalife, Hany Ragy, Ashraf Reda, Maichel Sobhy, Mostafa Nawar
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-03-01
Series:Cardiology and Therapy
Subjects:
Online Access:https://doi.org/10.1007/s40119-025-00400-0
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849733827143925760
author Mohamed Sobhy
Magdy Abdelhamid
Adel Mohamed El Etriby
Mohamed Fathy Soliman Gamaleldin
Ahmed Mohamed Helmy Youssef
Natasha Khalife
Hany Ragy
Ashraf Reda
Maichel Sobhy
Mostafa Nawar
author_facet Mohamed Sobhy
Magdy Abdelhamid
Adel Mohamed El Etriby
Mohamed Fathy Soliman Gamaleldin
Ahmed Mohamed Helmy Youssef
Natasha Khalife
Hany Ragy
Ashraf Reda
Maichel Sobhy
Mostafa Nawar
author_sort Mohamed Sobhy
collection DOAJ
description Abstract Introduction Real-world data on atrial fibrillation (AF) in the Middle East and North Africa (MENA) region, including Egypt, are sparse. The aim of the FLOW-AF registry was to evaluate the characteristics, treatment patterns, and clinical and economic outcomes of newly diagnosed non-valvular atrial fibrillation (NVAF) patients within the MENA region, including Egypt. Methods This multicenter, prospective, observational registry enrolled newly diagnosed patients with NVAF from January 2020 to December 2022 at eight private-sector healthcare centers in Egypt. Data were collected at enrollment (baseline), and then at 6-month and 12-month follow-up. Baseline data included demographics, AF characteristics, medical history, and antithrombotic treatment patterns. Follow-up data included clinical events, healthcare resource utilization, and related costs. Results A total of 723 patients were enrolled. Overall, 51.87% were females, and the mean age was 61.9 years. All patients attended the private health sector. The mean (standard deviation) CHA2DS2-VASc and HAS-BLED risk scores were 2.37 (1.55) and 1.46 (1.18), respectively. Non-vitamin K antagonist oral anticoagulants (62.52%), vitamin K antagonists (22.28%), and antiplatelet therapy (9.85%) were among the prescribed treatments. Rates of transient ischemic attack and all-cause mortality were 2.64% and 0.83%, respectively; all other outcomes (stroke, bleeding, myocardial infarction, systemic embolism) occurred at a rate of ≤ 0.41%. Antithrombotic medications were the major contributors to per-patient total yearly cost (USD 381.2). Conclusions The FLOW-AF study showed that patients with NVAF in Egypt are younger and exhibit lower mean baseline CHA2DS2-VASc and HAS-BLED scores compared to Western and other Eastern regions. Additional research, including a broader study population with a longer follow-up, is essential to comprehensively assess the characteristics and outcomes of the NVAF population in Egypt.
format Article
id doaj-art-516ddb3a0731492ba219e2ca81160ffb
institution DOAJ
issn 2193-8261
2193-6544
language English
publishDate 2025-03-01
publisher Adis, Springer Healthcare
record_format Article
series Cardiology and Therapy
spelling doaj-art-516ddb3a0731492ba219e2ca81160ffb2025-08-20T03:07:57ZengAdis, Springer HealthcareCardiology and Therapy2193-82612193-65442025-03-0114216118210.1007/s40119-025-00400-0The Atrial FibriLlatiOn Registry (FLOW-AF): Patient Characteristics, Treatment Patterns, and Outcomes in EgyptMohamed Sobhy0Magdy Abdelhamid1Adel Mohamed El Etriby2Mohamed Fathy Soliman Gamaleldin3Ahmed Mohamed Helmy Youssef4Natasha Khalife5Hany Ragy6Ashraf Reda7Maichel Sobhy8Mostafa Nawar9International Cardiac Center HospitalPrivate ClinicPrivate ClinicPfizer GulfPfizer EgyptDubai World Trade Center, IQVIA, Real-World EvidenceCardiocath Medical Private CenterPrivate ClinicPrivate Clinic, Cairo UniversityPrivate ClinicAbstract Introduction Real-world data on atrial fibrillation (AF) in the Middle East and North Africa (MENA) region, including Egypt, are sparse. The aim of the FLOW-AF registry was to evaluate the characteristics, treatment patterns, and clinical and economic outcomes of newly diagnosed non-valvular atrial fibrillation (NVAF) patients within the MENA region, including Egypt. Methods This multicenter, prospective, observational registry enrolled newly diagnosed patients with NVAF from January 2020 to December 2022 at eight private-sector healthcare centers in Egypt. Data were collected at enrollment (baseline), and then at 6-month and 12-month follow-up. Baseline data included demographics, AF characteristics, medical history, and antithrombotic treatment patterns. Follow-up data included clinical events, healthcare resource utilization, and related costs. Results A total of 723 patients were enrolled. Overall, 51.87% were females, and the mean age was 61.9 years. All patients attended the private health sector. The mean (standard deviation) CHA2DS2-VASc and HAS-BLED risk scores were 2.37 (1.55) and 1.46 (1.18), respectively. Non-vitamin K antagonist oral anticoagulants (62.52%), vitamin K antagonists (22.28%), and antiplatelet therapy (9.85%) were among the prescribed treatments. Rates of transient ischemic attack and all-cause mortality were 2.64% and 0.83%, respectively; all other outcomes (stroke, bleeding, myocardial infarction, systemic embolism) occurred at a rate of ≤ 0.41%. Antithrombotic medications were the major contributors to per-patient total yearly cost (USD 381.2). Conclusions The FLOW-AF study showed that patients with NVAF in Egypt are younger and exhibit lower mean baseline CHA2DS2-VASc and HAS-BLED scores compared to Western and other Eastern regions. Additional research, including a broader study population with a longer follow-up, is essential to comprehensively assess the characteristics and outcomes of the NVAF population in Egypt.https://doi.org/10.1007/s40119-025-00400-0Atrial fibrillationClinical outcomesEgyptHealthcare resource utilizationOral anticoagulants
spellingShingle Mohamed Sobhy
Magdy Abdelhamid
Adel Mohamed El Etriby
Mohamed Fathy Soliman Gamaleldin
Ahmed Mohamed Helmy Youssef
Natasha Khalife
Hany Ragy
Ashraf Reda
Maichel Sobhy
Mostafa Nawar
The Atrial FibriLlatiOn Registry (FLOW-AF): Patient Characteristics, Treatment Patterns, and Outcomes in Egypt
Cardiology and Therapy
Atrial fibrillation
Clinical outcomes
Egypt
Healthcare resource utilization
Oral anticoagulants
title The Atrial FibriLlatiOn Registry (FLOW-AF): Patient Characteristics, Treatment Patterns, and Outcomes in Egypt
title_full The Atrial FibriLlatiOn Registry (FLOW-AF): Patient Characteristics, Treatment Patterns, and Outcomes in Egypt
title_fullStr The Atrial FibriLlatiOn Registry (FLOW-AF): Patient Characteristics, Treatment Patterns, and Outcomes in Egypt
title_full_unstemmed The Atrial FibriLlatiOn Registry (FLOW-AF): Patient Characteristics, Treatment Patterns, and Outcomes in Egypt
title_short The Atrial FibriLlatiOn Registry (FLOW-AF): Patient Characteristics, Treatment Patterns, and Outcomes in Egypt
title_sort atrial fibrillation registry flow af patient characteristics treatment patterns and outcomes in egypt
topic Atrial fibrillation
Clinical outcomes
Egypt
Healthcare resource utilization
Oral anticoagulants
url https://doi.org/10.1007/s40119-025-00400-0
work_keys_str_mv AT mohamedsobhy theatrialfibrillationregistryflowafpatientcharacteristicstreatmentpatternsandoutcomesinegypt
AT magdyabdelhamid theatrialfibrillationregistryflowafpatientcharacteristicstreatmentpatternsandoutcomesinegypt
AT adelmohamedeletriby theatrialfibrillationregistryflowafpatientcharacteristicstreatmentpatternsandoutcomesinegypt
AT mohamedfathysolimangamaleldin theatrialfibrillationregistryflowafpatientcharacteristicstreatmentpatternsandoutcomesinegypt
AT ahmedmohamedhelmyyoussef theatrialfibrillationregistryflowafpatientcharacteristicstreatmentpatternsandoutcomesinegypt
AT natashakhalife theatrialfibrillationregistryflowafpatientcharacteristicstreatmentpatternsandoutcomesinegypt
AT hanyragy theatrialfibrillationregistryflowafpatientcharacteristicstreatmentpatternsandoutcomesinegypt
AT ashrafreda theatrialfibrillationregistryflowafpatientcharacteristicstreatmentpatternsandoutcomesinegypt
AT maichelsobhy theatrialfibrillationregistryflowafpatientcharacteristicstreatmentpatternsandoutcomesinegypt
AT mostafanawar theatrialfibrillationregistryflowafpatientcharacteristicstreatmentpatternsandoutcomesinegypt
AT mohamedsobhy atrialfibrillationregistryflowafpatientcharacteristicstreatmentpatternsandoutcomesinegypt
AT magdyabdelhamid atrialfibrillationregistryflowafpatientcharacteristicstreatmentpatternsandoutcomesinegypt
AT adelmohamedeletriby atrialfibrillationregistryflowafpatientcharacteristicstreatmentpatternsandoutcomesinegypt
AT mohamedfathysolimangamaleldin atrialfibrillationregistryflowafpatientcharacteristicstreatmentpatternsandoutcomesinegypt
AT ahmedmohamedhelmyyoussef atrialfibrillationregistryflowafpatientcharacteristicstreatmentpatternsandoutcomesinegypt
AT natashakhalife atrialfibrillationregistryflowafpatientcharacteristicstreatmentpatternsandoutcomesinegypt
AT hanyragy atrialfibrillationregistryflowafpatientcharacteristicstreatmentpatternsandoutcomesinegypt
AT ashrafreda atrialfibrillationregistryflowafpatientcharacteristicstreatmentpatternsandoutcomesinegypt
AT maichelsobhy atrialfibrillationregistryflowafpatientcharacteristicstreatmentpatternsandoutcomesinegypt
AT mostafanawar atrialfibrillationregistryflowafpatientcharacteristicstreatmentpatternsandoutcomesinegypt